

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17501-CON(AP)	SERIAL NO.: Not yet assigned
APPLICANT: Chang et al	COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE
FILING DATE: Submitted herewith	GROUP: Not yet assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
4	4,861,760	8/29/1989	Mazuel et al	1		
AB	6,248,741B1	6/19/2001	Wheeler et al			
AC	3,890,319	6/17/1975	Danielewicz et al			
AD	6,194,415B1	2/27/2001	Wheeler et al			
AE	5,856,329	1/5/1999	Wheeler et al			
AF	4,195,085	3/25/1980	Stone			
AG	6441047 B1	08/2002	Desantes, Jr.			
AH	6174524 B1	01/2001	Bawa et al.			
AI	6410045 B1	06/2002	Shultz et al.			
Q	AJ	6316441 BA	11/2001	Dean et al.		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AG					
	AH					
	AI					

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

6	AJ	"Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy", Stewart et al., Acta Ophthalmologica Scandinavia, 2002, 80(3), 277-281.
	AK	"Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination", Larsson, Lillinger, Archives of Ophthalmology, 2001, 119(4), 492-495.
	AL	"The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma", Yuksel et al., Ophthalmologica, 1999, 213(4), 228-233.
	AM	"A short term study of the additive effect of timolol and brimonidine on intraocular pressure", Arici et al., Eye, 2002, vol. 16, no. 1, pp. 39-43.
	AN	Sall et al., IOVS, 2001k, vol. 42, no. 4, pp. S822.
	AO	"Clinical Experience With Brimonidine 0.2% And Timolol 0.5% In Glaucoma And Ocular Hypertension", Schuman, Survey Of Ophthalmology, 1996, 41 Suppl 1 S27-37.
Q	AP	"Cardiovascular effects of timolol, brimonidine and brimonidine/timolol in combination", Jackson et al., IOVS, vol. 42, no. 4, pp. S418.
Q	AQ	"Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination", Larson, IOVS, 1999, vol. 40, no. 4, pp. S515.

EXAMINER Ba DATE CONSIDERED 11-30-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17501 CON (AP)	SERIAL NO.: Not yet assigned
APPLICANT: CHIN-MING CHANG, et al.	TITLE: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE
FILING DATE: Filed Herewith	GROUP: Not yet assigned

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (If applicable)
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						

### OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

5	CA	Hommer, A.B., et al., <i>Efficacy and Safety of Unoprostone, Dorzolamide, and Brimonidine in Adjunctive Therapy to Timolol in Patients with primary open-angle glaucoma and ocular hypertension</i> , Investigative Ophthalmology & Visual Science, Vol. 42, No. 4, Supp. Mar 15, 2001, Pg. 554,
	CB	Hoyng, P.F., et al., <i>Pharmacological Therapy of glaucoma</i> , Drugs, Vol. 59, No. 3, March 2000 pgs. 411-434
	CC	Larson, L.I., <i>Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination</i> , Arch Ophthalmol/ Vol. 119, Apr 2001, pg. 492-495
	CD	Schuman, J.S., <i>Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension</i> , Survey of Ophthalmology, Vo. 41, Supp. 1, Noember 1996, pg. s27-s37
	CE	Stewart, W.C., <i>Perspectives in the medical treatment of glaucoma</i> , Current Opinion in Ophthalmology, Vol. 10, No. 2, April 1999, pp. 99-109
	CF	Wang, R.F., et al., <i>Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes</i> , J. of Glaucoma 9:458-62
1	CG	Yukse,N., et al., <i>The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma</i> , Ophthalmologica, Vol. 213 (1999), pgs. 228-233.

EXAMINER Bil

DATE CONSIDERED 11-30-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
FORM PTO-1449

Sheet 1 of 1

## LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17501CON(AP)	SERIAL NO.: 10/685,941
APPLICANT: Chang et al	TITLE: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE
FILING DATE: October 14, 2003	GROUP: Not Known

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (If applicable)

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

## OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

13	BA	Craven et al, "Efficacy and Safety of the IOP-Lowering Fixed Combination Brimonidine 0.2%/Timolol 0.5%, M200510403E.1.doc, one page, 2005
----	----	---

EXAMINER B21 DATE CONSIDERED 11-30-05  
 \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.